Présentation de l'entreprise
Agenus Inc. operates as a clinical-stage biotechnology entity dedicated to the discovery and development of immunotherapies designed to treat cancer and infectious diseases within the United States and international markets. The company leverages its proprietary Retrocyte Display platform, an antibody expression system utilized for the identification of fully human and humanized monoclonal antibodies, to advance its research pipeline. This business model situates Agenus within the broader healthcare sector, specifically the biotechnology industry, where innovation in therapeutic mechanisms is critical for market differentiation. With a market capitalization of $161.27M, annual revenue of $114.20M, and a workforce of 81 employees, the company maintains a niche position characterized by significant revenue generation relative to its asset base. The valuation metrics suggest that despite operating with a small team, the firm has achieved substantial revenue recognition, indicating a high efficiency in resource utilization typical of early-stage biotech firms that have successfully moved beyond initial discovery phases.
Santé financière
The company reported a revenue of $114.20M for the trailing twelve months, accompanied by a net income of $-101,000 and an EBITDA of $-10,557,000. The substantial disparity between the positive revenue figure and the negative net income reveals a cost structure dominated by operating expenses that outweigh gross profits, a common characteristic in the clinical development stage of biotechnology. Free cash flow stands at $-83,003,752, indicating that the company is currently burning cash to fund its operations and research activities rather than generating liquidity for dividends or share buybacks. The balance sheet reflects a gross margin of 96.5%, demonstrating the high value of the company's products relative to their cost of goods sold, while an operating margin of 42.1% suggests efficient management of operating costs before interest and taxes. However, a profit margin of 0.1% underscores the company's current lack of profitability on a bottom-line basis. Total cash on hand amounts to $3.00M, which is significantly lower than the total debt of $55.92M, creating a leverage situation that requires careful monitoring of cash burn rates. Although the debt-to-equity ratio is listed as N/A, the disparity between liquid assets and liabilities suggests a reliance on equity financing or other non-debt obligations to support operations. The current ratio is reported at 0.41, indicating that current liabilities exceed current assets, which signals potential short-term liquidity challenges that must be addressed through future financing or operational improvements. Return on Equity is N/A due to the company's capital structure, while the return on assets stands at -5.7%, reflecting the negative impact of high expenses on the utilization of the company's total assets.
Évaluation de la valorisation
The trailing P/E ratio is N/A, while the forward P/E is reported as -1.83, a metric that implies the market is pricing in future earnings expectations that could eventually turn positive as the company progresses through clinical trials. The price-to-book ratio is -0.55, a negative figure that typically indicates the company's market capitalization is lower than its book value, often seen in unprofitable firms where assets are undervalued or liabilities are high. The price-to-sales ratio stands at 1.41, providing a valuation metric that is independent of profitability and suggests the market values the company at roughly one and a half times its annual sales. Additionally, the EV/EBITDA ratio is -19.65, which highlights the company's negative earnings power and suggests that traditional valuation multiples based on earnings are not applicable at this stage. The stock has traded between a 52-week low of $1.56 and a 52-week high of $7.34, meaning the current price sits within a range that reflects high volatility typical of small-cap biotechnology stocks. The beta value is 1.61, indicating that the stock price is expected to be 61% more volatile than the broader market, amplifying both potential gains and losses during periods of market movement.
Growth & Income
Revenue growth year-over-year is recorded at 27.5%, demonstrating a strong expansion in sales driven by the commercialization of its immunotherapy products, whereas earnings growth is N/A due to the company's current lack of profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings, however small, are effectively reinvested into research and development or retained to strengthen the balance sheet. The absence of a dividend policy is consistent with the growth strategy of a clinical-stage biotechnology firm that prioritizes funding its pipeline over returning capital to shareholders. Consequently, the overall growth and income profile of Agenus Inc. is defined by robust top-line expansion supported by a reinvestment strategy rather than income generation through dividends or significant earnings growth.